What should I know first?

Memantine affects the NMDA receptor/channel, which participates in glutamate signalling. Glutamate is a chemical messenger used widely in the nervous system.

The UK Ebixa product information covers moderate to severe Alzheimer’s disease. That does not mean that any memory difficulty is an indication, or that every medicine affecting NMDA receptors has the same clinical use.

This is a mechanism lesson, not a complete medicine guide. A diagram cannot choose treatment, predict your response, or tell you how to change a prescription.

How Brain Cells Communicate

NMDA is one type of receptor that responds within glutamate signalling. It also forms a channel through which positively charged ions can move when the activation conditions are met.

Glutamate signalling has normal functions. It should not be described as a toxin that the brain needs to remove completely. A single messenger is not a complete explanation of Alzheimer’s disease.

An open NMDA-receptor channel with agonist symbols outside and sodium/calcium ion symbols in a pore. Activation requirements are simplified. Sodium / calcium · Na⁺ / Ca²⁺: This example shows inward movement of positively charged ions. NMDA glutamate receptor / channel: The pore opens under appropriate activation conditions. Open channel: The arrow shows a qualitative direction, not an ion count or measured rate.
  1. Sodium / calcium · Na⁺ / Ca²⁺

    This example shows inward movement of positively charged ions.

  2. NMDA glutamate receptor / channel

    The pore opens under appropriate activation conditions.

  3. Open channel

    The arrow shows a qualitative direction, not an ion count or measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Qualitative NMDA channel model, not atomic geometry. Target action is not evidence of slowing neurodegeneration.
About this illustration

Under the appropriate activation conditions, an NMDA receptor channel permits positively charged ions to pass. The arrow shows a teaching example of inward current.

How the Medication Changes Signalling

Memantine is an uncompetitive, open-channel NMDA receptor antagonist. In plain language, its blocking action is associated with channels that have opened. It can limit current through these channels.

The bar on the diagram means reduced passage in this teaching model. It is not a measured atomic site, a permanently sealed channel, or a command to eliminate all NMDA activity.

A Closer Look at the Molecular Level

UK product information describes voltage-dependent, uncompetitive NMDA receptor antagonism. A proposed role for altered glutamate signalling in Alzheimer’s disease is not the same as demonstrating the cause of an individual’s symptoms.

Memantine can help with symptoms but does not cure Alzheimer’s disease. A channel action does not prove that it stops underlying degeneration. Benefits and burdens require clinical review rather than interpretation of a schematic.

Sources and References

  1. Ebixa 10 mg film-coated tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. What Is a Neurotransmitter?

    Scope: International scientific education; not UK regulatory evidence.

  3. Memantine

    Scope: United Kingdom medicine education.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top